Hepatitis C Group Rejects Settlement Offer By Japanese Government, Drug Makers (Japan)
This article was originally published in PharmAsia News
Executive Summary
A group of people infected with hepatitis C after receiving contaminated blood has rejected a settlement agreement offered by drug makers and the Japanese government. The group is comprised of 13 patients out of an estimated 200 plaintiffs who contracted the disease after receiving the blood. The 13-member group said it rejected the offer because it would not properly compensate some of the 200. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.